Orthofix Medical Inc. (NASDAQ: OFIX) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.51 | Insider Own | 28.83% | Shs Outstand | 40.42M | Perf Week | 4.89% |
| Market Cap | 476.98M | Forward P/E | - | EPS next Y | -0.88 | Insider Trans | 0.44% | Shs Float | 40.10M | Perf Month | 26.20% |
| Enterprise Value | 591.08M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 6.26% | Perf Quarter | 0.34% |
| Income | -59.96M | P/S | 0.58 | EPS this Y | 22.32% | Inst Trans | - | Short Ratio | 6.10 | Perf Half Y | -10.13% |
| Sales | 825.42M | P/B | 1.10 | EPS next Y | 24.75% | ROA | -6.77% | Short Interest | 2.51M | Perf YTD | -22.16% |
| Book/sh | - | P/C | 13.67 | EPS next 5Y | - | ROE | -13.44% | 52W High | 17.65 -30.55% | Perf Year | 3.87% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -4.59% | 52W Low | 9.20 33.33% | Perf 3Y | -39.83% |
| Dividend Est. | - | EV/EBITDA | 6.25 | Sales past 3/5Y | 21.26% 15.09% | Gross Margin | 69.02% | Volatility | 4.72% 4.96% | Perf 5Y | -69.12% |
| Dividend TTM | - | EV/Sales | 0.72 | EPS Y/Y TTM | 54.24% | Oper. Margin | -4.03% | ATR (14) | 0.56 | Perf 10Y | -74.92% |
| Dividend Ex-Date | - | Quick Ratio | 1.76 | Sales Y/Y TTM | 3.38% | Profit Margin | -7.27% | RSI (14) | 57.24 | Recom | 2.65 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.87 | EPS Q/Q | -550.00% | SMA20 | 1.82% | Beta | 0.69 | Target Price | 16.00 |
| Payout | 0.00% | Debt/Eq | 0.54 | Sales Q/Q | 1.55% | SMA50 | 13.03% | Rel Volume | 0.60 | Prev Close | 11.80 |
| Employees | 1,605 | LT Debt/Eq | 0.50 | Earnings | Aug 05 | SMA200 | -8.83% | Avg Volume | 424.06K | Price | 12.26 |
| IPO Date | Apr 24, 1992 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 23.53% 0.16% | Net Debt/EBITDA | 1.21 | Volume | 256,331 | Change | 3.90% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-06-26 | Reiterated | Barrington Research | Outperform | $15 → $17 |
| May-22-26 | Reiterated | UBS | $18 → $15 | |
| May-22-26 | Reiterated | Barrington Research | Outperform | $18 → $15 |
| May-21-26 | Reiterated | Cowen & Co. | $14 → $12 | |
| Mar-09-26 | Reiterated | Stifel Nicolaus | $22 → $18 | |
| Nov-05-25 | Reiterated | Barrington Research | Outperform | $18 |
| Oct-28-25 | Resumed | Stifel | Buy | $22 |
| Nov-08-24 | Reiterated | Stifel Nicolaus | $31 → $24 | |
| Nov-08-24 | Upgrade | Stifel | Hold → Buy | |
| May-08-24 | Upgrade | Roth MKM | Neutral → Buy |
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 826 | 822 | 799 | 747 | 461 | 464 | 407 | 460 | 453 | |
| Cost of Goods Sold Incl. D&A | 256 | 271 | 254 | 260 | 124 | 115 | 102 | 101 | 97 | |
| Gross Profit | 571 | 552 | 546 | 486 | 337 | 350 | 305 | 359 | 356 | |
| Selling, General and Administrative Excl. Other | 556 | 456 | 533 | 530 | 309 | 291 | 272 | 309 | 290 | |
| Research and Development | 61 | 57 | 74 | 80 | 49 | 50 | 39 | 35 | 33 | |
| Other Operating Expense | -13 | 107 | 24 | 15 | -8 | 17 | 0 | 34 | 0 | |
| Operating Income | -34 | -68 | -85 | -139 | -13 | -8 | -6 | -19 | 30 | |
| Interest Expense | 19 | 17 | 30 | 9 | 1 | 2 | 2 | 0 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -7 | -5 | -10 | -1 | -3 | -3 | 8 | -8 | -6 | |
| Net Income Before Taxes | -59 | -91 | -124 | -149 | -18 | -13 | 0 | -27 | 23 | |
| Income Taxes | 1 | 1 | 2 | 3 | 2 | 25 | -3 | 1 | 9 | |
| Consolidated Net Income | -60 | -92 | -126 | -151 | -20 | -38 | 3 | -28 | 14 | |
| Net Income From Continuing Operations | -60 | -92 | -126 | -151 | -20 | -38 | 3 | -28 | 14 | |
| Net Income | -60 | -92 | -126 | -151 | -20 | -38 | 3 | -28 | 14 | |
| EPS (Recurring) | -1.51 | -2.28 | -3.30 | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.75 | |
| EPS (Basic, Before Extraordinaries) | -1.51 | -2.28 | -3.30 | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.75 | |
| EPS (Diluted) | -1.51 | -2.28 | -3.30 | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.73 | |
| EBITDA | 95 | -22 | -34 | -79 | 16 | 21 | 36 | 2 | 42 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | 330.62 | — | 71.90 | |
| Price To Sales Ratio | 0.59 | 0.74 | 0.83 | 0.67 | 0.89 | 1.34 | 2.01 | 1.91 | 2.09 | |
| Gross Margin | 69.13 | 67.15 | 68.34 | 65.06 | 73.10 | 75.43 | 74.94 | 78.04 | 78.59 | |
| Operating Margin | -4.12 | -8.27 | -10.64 | -18.61 | -2.82 | -1.72 | -1.47 | -4.13 | 6.62 | |
| Net Margin | -7.26 | -11.19 | -15.77 | -20.21 | -4.34 | -8.19 | 0.74 | -6.09 | 3.09 | |
| Shares Outstanding | 40 | 40 | 38 | 37 | 20 | 20 | 19 | 19 | 18 | |
| Market Capitalization | 490 | 606 | 663 | 499 | 411 | 622 | 817 | 877 | 945 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McPherron Aviva | Pres, Global Ops & Qual | Jun 18 '26 | Sale | 9.38 | 3,670 | 34,425 | 66,330 | Jun 22 |
| Juniper Investment Company, LLC | 10% Owner | May 22 '26 | Sale | 10.70 | 242,000 | 2,589,206 | 3,461,216 | May 29 |
| HENNEMAN JOHN B III | Director | May 07 '26 | Buy | 12.26 | 5,000 | 61,295 | 90,809 | May 08 |
| Engine Capital Management, LP | 10% Owner | May 07 '26 | Buy | 12.18 | 30,000 | 365,425 | 3,848,573 | May 07 |
| Engine Capital Management, LP | 10% Owner | May 06 '26 | Buy | 12.23 | 41,946 | 512,916 | 3,821,285 | May 07 |
| Engine Capital Management, LP | 10% Owner | May 05 '26 | Buy | 11.99 | 112,950 | 1,354,587 | 3,783,131 | May 07 |
| Cedron Jorge Andres | CLO | Apr 16 '26 | Sale | 12.82 | 3,743 | 47,985 | 59,006 | Apr 20 |
| Vitale Lucas | CP&BOO | Mar 17 '26 | Sale | 11.92 | 4,269 | 50,886 | 160,449 | Mar 19 |
| CAPPS VICKIE L | Director | Mar 10 '26 | Buy | 12.45 | 2,500 | 31,124 | 27,585 | Mar 10 |
| CAPPS VICKIE L | Director | Mar 09 '26 | Buy | 12.48 | 2,500 | 31,200 | 25,085 | Mar 10 |
| Fisher Patrick | President, Global Limb Recon | Mar 05 '26 | Sale | 12.55 | 758 | 9,514 | 50,633 | Mar 06 |
| Andrews Julie | CFO | Mar 05 '26 | Sale | 12.55 | 2,363 | 29,658 | 88,746 | Mar 06 |
| Cedron Jorge Andres | CLO | Mar 05 '26 | Sale | 12.55 | 1,370 | 17,195 | 62,749 | Mar 06 |
| Vitale Lucas | CP&BOO | Mar 05 '26 | Sale | 12.55 | 1,141 | 14,320 | 164,718 | Mar 06 |
| REINHARDT MAX | President, Global Spine | Mar 05 '26 | Sale | 12.55 | 1,053 | 13,216 | 25,348 | Mar 06 |